You are here: Industry Insights > myeloma

News List

Five-drug combination for ultra-high-risk bone marrow cancer identified PharmaTimes
December 14, 2021
A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.
Scientists identify new types of a blood cancer and potential targeted treatments WorldPharmaNews
December 01, 2021
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple...
Four-drug combo therapy shows benefit for newly-diagnosed myeloma patients pharmatimes
July 27, 2021
A four-drug combination therapy has shown significant benefit for patients with newly diagnosed myeloma, according to a new analysis led by researchers from The Institute of Cancer Research, London (ICR).
J&J, Legend's CAR-T therapy cilta-cel granted priority review by FDA firstwordpharma
May 27, 2021
The FDA has accepted a marketing application for Johnson & Johnson and partner Legend Biotech's BCMA-directed CAR-T therapy ciltacabtagene autoleucel (cilta-cel) for priority review as a potential treatment of adults with relapsed and/or refractory
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines prnasia
May 06, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese ...
Multiple myeloma treatment granted Orphan Drug Designation europeanpharmaceuticalreview
September 19, 2019
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
Glenmark Receives Orphan Drug Designation for Multiple Myeloma Candidate americanpharmaceuticalreview
September 18, 2019
Glenmark announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its bispecific antibody candidate GBR 1342 for the treatment of patients with multiple myeloma ...
DARZALEX® Study Data Show High Response Rate americanpharmaceuticalreview
September 17, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib ...
Multiple myeloma treatment receives Orphan Drug Designation europeanpharmaceuticalreview
September 03, 2019
Orphan drug designation has been granted to the CT053 anti-BCMA CAR-T program for multiple myeloma treatment.
Salvage Therapy Does Not Up Survival for Progressive Myeloma drugs
August 29, 2019
For myeloma patients with progressive disease (PD) after induction therapy, deepening of response through salvage therapy is not associated with improved progression-free or overall survival...

Previous page 1 2 3 4 Next page